Herbert Smith Freehills (Shanghai)

Frances Xu

Herbert Smith Freehills (Shanghai)
Partner

Prior to joining Kewei, Frances was a counsel at a leading law firm in China, heading its antitrust practice. She has also worked for the Competition and Consumer Protection Policy unit under the United Nations Conference on Trade & Development (UNCTAD) and the Price Supervision and Anti-monopoly Bureau under the National Development and Reform Commission (now consolidated in the State Administration for Market Regulation). She was the main drafter of the Guidelines on General Conditions and Procedures for the Exemption of Monopoly Agreements of the Antimonopoly Commission of the State Council. She obtained her doctorate in competition law from the China University of Political Science and Law and her master’s degree in international business law from the National University of Singapore. Admitted to practise law in China, she is fluent in English and Chinese.

Linked authors

Herbert Smith Freehills (Melbourne)
Herbert Smith Freehills (London)
Herbert Smith Freehills (Johannesburg)
Herbert Smith Freehills (London)
Herbert Smith Freehills (London)

Articles

1712 Bulletin

Adelaide Luke, Howard Chan, Joel Rheuben, Frances Xu The Hong Kong Competition Authority launches first enforcement proceedings in relation to resale price maintenance (Tien Chu)

293

Introduction On 15 September 2022, the Competition Commission (Hong Kong) (the “Commission”) commenced its first enforcement proceedings in relation to resale price maintenance (“RPM”) arrangements against a food manufacturer, The Tien Chu (Hong Kong) Company Limited (“Tien Chu”). What is RPM? (...)

Adelaide Luke, Frances Xu, Howard Chan, Hazel Xu The Chinese State Administration for Market Regulation launches public consultations on its proposed amendments to administrative sanctions for price-related illegal activities with special focus on the digital sector

219

The State Administration for Market Regulation (SAMR), China’s primary competition enforcement regulator, recently published a consultation draft of its amendments to the existing Provisions on Administrative Sanctions Against Price-related Illegal Activities on 2 July 2021 (the Provisions). The (...)

Adelaide Luke, Howard Chan, Frances Xu The Chinese State Administration for Market Regulation fines three internet companies for failure to notify past merger transactions under the merger control regime in breach of the Anti-Monopoly Law (Alibaba / China Literature / Shenzhen)

212

On 14 December 2020, China’s State Administration for Market Regulation (SAMR) imposed fines against three internet based companies Alibaba Investment Limited, China Literature Limited and Shenzhen Hive-box Network Technology for respective failures to notify past transactions under the merger (...)

Adelaide Luke, Frances Xu, Howard Chan, Hazel Xu The Chinese State Administration for Market Regulation consolidates previous merger control guidance in its new Interim Provisions on Undertaking Concentration Examination

143

On 27 October 2020, China’s State Administration for Market Regulation (SAMR) issued the Interim Provisions on Undertaking Concentration Examination (Provisions), which will come into force on 1 December 2020. As well as consolidating previous guidance published by its predecessor, the Ministry (...)

Adelaide Luke, Frances Xu, Howard Chan, Hazel Xu The Chinese State Administration for Market Regulation publishes long-awaited antitrust guidelines on leniency, auto sector and IP

84

In August 2020, China’s chief competition enforcement agency, the State Administration for Market Regulation (SAMR), announced the publication of the ‘2019 Compilation of Antitrust Regulations and Guidance’ (《2019年反垄断规章和指南汇编》). This publication formally adopts four key guidelines (the Guidelines) (...)

Frances Xu, Adelaide Luke, Frederick Good The Chinese State Administration for Market Regulation fines 3 pharmaceutical companies for abuse of dominance in the distribution of an injectable drug and confirms that pharmaceuticals and medical devices sectors continue to be an enforcement priority amid the COVID-19 outbreak (Kanghui / Puyunhui / Taiyangshen)

761

On 9 April 2020, China’s State Administration for Market Regulation (SAMR) fined 3 pharmaceutical companies for abuse of dominance in the distribution of injectable calcium gluconate Active Pharmaceutical Ingredient (API). The three companies were found to be in breach of the PRC’s Anti-Monopoly (...)

Send a message